



## **SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2022 on May 10, 2022**

April 13, 2022

BOSTON and LAUSANNE, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time.

The call will be webcast live on the [SOPHiA GENETICS Investor Relations website](#). Additionally, a replay will be available on the website after its completion.

### **About SOPHiA GENETICS**

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit [SOPHiAGENETICS.COM](#), or connect on [Twitter](#), [LinkedIn](#) and [Instagram](#). **Where others see data, we see answers.**

#### **Investor Contact:**

Jennifer Pottage  
Head of Investor Relations  
[Jpottage@sophiagenetics.com](mailto:Jpottage@sophiagenetics.com)

#### **Media Contact:**

Eliza Bamonti  
Director of Public Relations  
[Ebamonti@sophiagenetics.com](mailto:Ebamonti@sophiagenetics.com)